Toulose, France Clinical Trials

A listing of Toulose, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 133 clinical trials
featured
A Phase 2 Study of INCMGA00012 in Participants With Squamous Carcinoma of the Anal Canal Who Have Progressed Following Platinum-Based Chemotherapy

The purpose of this study is to assess the efficacy of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy.

platinum-based chemotherapy
measurable disease
chemotherapy regimen
Hospital General Universitari Vall D Hebron
 (154.0 away) Contact site
  • 64 views
  • 23 Nov, 2020
  • +23 other locations
featured
A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Plus Pembrolizumab Versus Pemigatinib Alone Versus Standard of Care as First-Line Treatment for Metastatic or Unresectable Urothelial Carcinoma in Cisplatin-Ineligible Participants Whose Tumors Express FGFR3 Mutation or Rearrangement

The purpose of this study is to evaluate the safety and efficacy of pemigatinib plus pembrolizumab or pemigatinib alone versus the standard of care for participants with metastatic or unresectable urothelial carcinoma who are not eligible to receive cisplatin, are harboring FGFR3 mutation or rearrangement, and who have not received …

bladder cancer
urothelial carcinoma
metastatic urothelial carcinoma
bladder carcinoma
Institut Claudius Regaud Oncopole Toulouse
 (0.0 away) Contact site
  • 29 views
  • 14 Dec, 2020
  • +63 other locations
featured
A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

urinary tract cancer
Research Center
 (0.3 away) Contact site
  • 1071 views
  • 25 Aug, 2021
  • +39 other locations
featured
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828 at 13.5 mg on a 2-week-on–therapy and 1-week-off–therapy schedule.  With Protocol Amendment 3, the administration schedule will be adjusted, and newly enrolled subjects will …

lymphoid malignancy
FGFR1
myeloid neoplasm
Institut Universitaire du Cancer de Toulouse - Oncopole
 (0.0 away) Contact site
  • 80 views
  • 14 Dec, 2020
  • +34 other locations
featured
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.  

malignancies
administration intravenous
primary tumor
primary cancer
malignancy
Institut Claudius Regaud Oncopole Toulouse
 (0.0 away) Contact site
  • 46 views
  • 25 Aug, 2021
  • +56 other locations
Surgery in Treating Patients With Neuroblastoma

RATIONALE: Surgery may be an effective treatment for neuroblastoma. PURPOSE: This phase II trial is studying how well surgery works in treating patients with neuroblastoma.

Centre Hospitalier Regional de Purpan
 (2.0 away) Contact site
  • 73 views
  • 07 Nov, 2020
  • +18 other locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

Institut Claudius R gaud
 (0.5 away) Contact site
  • 2 views
  • 23 Sep, 2021
  • +77 other locations
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

The purpose of this study is to evaluate the objective response rate (complete response [CR]+ partial response [PR]) of the selected dose regimen in participants with metastatic or surgically unresectable urothelial cancers that harbor specific FGFR genomic alterations.

erdafitinib
adjuvant chemotherapy
dose regimen
measurable disease
renal function
Institut Bergoni
 (131.0 away) Contact site
  • 40 views
  • 17 Sep, 2021
  • +157 other locations
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=) 2 to less than () 18 years of age with Pulmonary Arterial Hypertension (PAH), …

endothelin
connective tissue disease
endothelin receptor antagonist
right heart catheterization
selexipag
HOSP ARNAUD DE VILLENEUVE - PAED DEPT (Montpellier)
 (116.2 away) Contact site
  • 34 views
  • 10 Sep, 2021
  • +93 other locations
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment

The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated second line therapy). The main goal of this study is to evaluate …

Centre Hospitalier Lyon Sud
 (106.4 away) Contact site
  • 0 views
  • 22 Sep, 2021
  • +12 other locations